Monday, 28 May 2018

You are here

Chondroitin Effective in Knee OA. Or is it?

Reginster and colleagues have reported on the results of the CONCEPT trial showing that osteoarthritis (OA) patients treated 800 mg/day of  pharmaceutical-grade chondroitin sulfate (CS) have less VAS pain scores and improved function over 6 months therapy. These results were superior to placebo and equivalent to celecoxib in reducing in symptomatic OA knee pain.

They enrolled 603 OA knee patients a 6-month, 3-arm, double-blind, double-dummy trial were patients were randomized to either placebo, CS and celecoxib (200 mg/day). After 6 mos, greater improvement in Pain VAS scores were seen with CS (-42.6 mm) and celecoxib (−39.5 mm) versus those treated with placebo (−33.3 mm) (p=0.001 for CS and p=0.009 for celecoxib vs PBO).

Figure 2 

So is chondroitin as effective as NSAID therapy?  The problem is that many prior studies of CS use in knee OA have yielded mixed results. ( Citation source: http://buff.ly/2rqc0hE)

These data are limited by fair low effect size, the trial being sponsored by the CS manufacturer and prior claims showing selective benefit of a specific manufacturer compared to other manufacturers.

While the results are encouraging, further study by other parties is advisable.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Restless Sleep and Inactivity Intertwined in OA

Adults with osteoarthritis (OA) of the knee who frequently experienced restless sleep were less likely to engage in potentially beneficial moderate-to-vigorous physical activity, analysis of data from the Osteoarthritis Initiative found.

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Bisphosphonate Drug Holidays May Result in Fractures

A report in Endocrine Practice shows that drug holidays from bisphosphonates results in a 15% risk of fractures.  (Citation source: http://bit.ly/2FHbFwp)

USPSTF Recommendations on Vitamin D, Calcium Supplementation to Prevent Fractures

The U.S. Preventive Services Task Force (USPSTF) concludes current scientific evidence is insufficient regarding the use of vitamin D and calcium, alone or in combination, to prevent fractures in men and premenopausal women. The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D and 1,000 mg or less of calcium to prevent fractures in postmenopausal women. Current scientific evidence is insufficient regarding the use of vitamin D and calcium at doses greater than 400 IU of vitamin D and greater than 1,000 mg of calcium in postmenopausal women.

Obesity Surgery Tames Knee OA Pain

Laparoscopic gastric band (LAGB) surgery was associated with significant decreases in knee pain from osteoarthritis (OA), with the greatest improvements seen among those whose body mass index (BMI) had the greatest decreases and among younger patients, researchers reported.